• HER2 amplification studied in resectable CRC

    A study of 3,607 patients with resectable colorectal cancer investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy efficacy and circulating tumor DNA. (Int J Clin Oncol)